Sweden · Delayed Price · Currency is SEK Xvivo Perfusion AB Earnings Call Transcripts
Fiscal Year 2026
-
Record Q1 sales with 23% organic growth and strong cash flow, driven by robust thoracic and abdominal segment performance. Regulatory milestones for Heart Assist and Liver Assist are progressing, with significant clinical trial successes and expanding adoption in key markets.
-
Aims to revolutionize organ transplantation by increasing organ availability and improving outcomes through advanced perfusion technologies. Heart product launch and regulatory milestones are key upcoming drivers, with a strong focus on expanding market reach and service offerings.
Fiscal Year 2025
-
Q4 2025 saw 10% organic growth and record EBITDA margin, with strong performance in thoracic and abdominal segments. Strategic investments and restructuring are set to drive growth in 2026, though profitability will be moderated by expansion efforts. Regulatory milestones for heart and liver products remain key.
-
Q3 2025 saw 6% organic growth (excluding Heart trial revenue), strong abdominal segment performance, and EBITDA recovery. Strategic investments in U.S. services and partnerships aim to drive future growth, while regulatory timelines for Heart and Liver remain key uncertainties.
-
Q2 2025 saw negative top-line growth due to lung market slowdown, destocking, and currency headwinds, but strong growth in U.S. lung, kidney, and European liver segments. Regulatory progress and clinical milestones support a positive long-term outlook, with investments focused on field force and production scaling.
-
Q1 2025 saw strong sales and margin improvements, with key regulatory approvals in the US and Canada. Thoracic and abdominal segments posted double-digit growth, while investments and production expansion support future launches. Cash position remains solid.
Fiscal Year 2024
-
Record sales and profitability were achieved in Q4 2024, driven by strong growth in thoracic and abdominal segments, robust clinical adoption, and continued investment in expansion. Regulatory milestones and new product launches are expected to fuel further growth in 2025.
-
Q3 2024 saw 41% organic sales growth and improved margins, led by strong thoracic and U.S. EVLP performance. Strategic investments in production, clinical trials, and digital services position the company for continued expansion, with new product launches and regulatory milestones ahead.
-
Record Q2 sales and profitability driven by strong growth in thoracic and abdominal segments, with robust clinical and market momentum. Production scale-up and regulatory progress remain on track, supporting a positive outlook despite seasonal Q3 softness.